Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome associated with high-dose interleukin-2 for the treatment of metastatic melanoma

Journal of Immunotherapy

Volumn 28, Issue 2, 2005, Pages 144-147

  Alexandrescu, Doru T ^a,b   Maddukuri, Prasad ^a   Wiernik, Peter H ^a   Dutcher, Janice P ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b OUR LADY OF MERCY MEDICAL CENTER   (United States)

Author keywords

Hemolytic uremic syndrome; Interleukin 2; Malignant melanoma; Thrombotic thrombocytopenic purpura

Indexed keywords

ALPHA INTERFERON; DEXAMETHASONE; ETIRACETAM; INTERLEUKIN 1; INTERLEUKIN 2; LACTATE DEHYDROGENASE; PACLITAXEL; PHENYTOIN; TEMOZOLOMIDE; THALIDOMIDE; VENLAFAXINE; VEROTOXIN 1;

ADULT; ANAMNESIS; ARTICLE; BRAIN RADIATION; CHRONIC MYELOID LEUKEMIA; CYTOPENIA; ESCHERICHIA COLI; HEMOLYTIC UREMIC SYNDROME; HEPATITIS B; HUMAN; HYPOTENSION; LEUKOCYTE COUNT; MALE; MELANOMA; PLASMAPHERESIS; PRIORITY JOURNAL; RETICULOCYTE COUNT; SEIZURE; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; UREA NITROGEN BLOOD LEVEL;

EID: 14744269012     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000154250.82007.4a     Document Type: Article

References (25)

1. Iyoda K, Kato M, Nakagawa T, et al. Thrombotic thrombocytopenic purpura developed suddenly during interferon treatment for chronic hepatitis C. J Gastroenterol. 1998;33:588-592.
2. Al-Zahrani H, Gupta V, Minden MD, et al. Vascular events associated with alpha interferon therapy. Leuk Lymphoma. 2003;44:471-475.
3. Lacotte L, Thierry A, Delwail V, et al. Thrombotic thrombocytopenic purpura during interferon alpha treatment for chronic myelogenous leukemia. Acta Haematol. 2000;102:160-162.
4. Ravandi-Kashani F, Cortes J, Talpaz M, et al. Thrombotic microangiopathy associated with interferon therapy for patients withchronic myelogenous leukemia: coincidence or true side effect? Cancer. 1999;85:2583-2588.
5. Rachmani R, Avigdor A, Youkla M, et al. Thrombotic thrombocytopenic purpura complicating chronic myelogenous leukemia treated with interferon-alpha. A report of two successfully treated patients. Acta Haematol. 1998;100:204-206.
6. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976;193:1007-1008.
7. Vial T, Choquet-Kastylevsky G, Descotes J. Adverse effects of immunotherapeutics involving the immune system. Toxicology. 2002;174:3-11.
8. Shah NT, Rand JH. Controversies in differentiating thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Mt Sinai J Med. 2003;70:344-351.
9. Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol. 2002;107:133-144.
10. Catizone L, Santoro A, Scialfa G, et al. Thrombotic thrombocytopenic purpura due to administration of Ibuprofen. Minerva Nefrol. 1974;21:439-444.
11. Kallal SM, Lee M. Thrombotic thrombocytopenic purpura associated with histamine H2-receptor antagonist therapy. West J Med. 1996;164:446-448.
12. Bhagwati N, Seno R, Dutcher JP, et al. Fulminant metastatic melanoma complicated by a microangiopathic hemolytic anemia. Hematopathol Mol Hematol. 1998;11:101-108.
13. Murgo AJ. Thrombotic microangiopathy in the cancer patient including those induced biochemotherapeutic agents. Semin Hematol. 1987;24:161-177.
14. Wada H, Kaneko T, Ohiwa M, et al. Plasma cytokine levels in thrombotic thrombocytopenic purpura. Am J Hematol. 1992;40:167-170.
15. Siegler RL, Pysher TJ, Lou R, et al. Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome. Am J Nephrol. 2001;21:420-425.
16. Yamamoto T, Nagayama K, Satomura K. et al. Increased serum IL-10 and endothelin levels in hemolytic uremic syndrome caused by Escherichia coli O157. Nephron. 2000;84:326-332.
17. Taylor JL, Grossberg SE. The effects of interferon-alpha on the production and action of other cytokines. Semin Oncol. 1998;25(Suppl 1):23-29.
18. Baars JW, Wolbink GJ, Hart MH, et al. The release of interleukin-8 during intravenous bolus treatment with interleukin-2. Ann Oncol. 1994;5:929-934.
19. Lim SH, Worman C, Jewell A, et al. Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias. Cancer Immunol Immunother. 1991;33:133-137.
20. Economou JS, Hoban M, Lee JD, et al. Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity. Cancer Immunol Immunother. 1991;34:49-52.
21. Grimm EA, Smid CM, Lee JJ, et al. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin Cancer Res. 2000;6:3895-3903.
22. Carlsen E, Flatmark A, Prydz H. Cytokine-induced procoagulant activity in monocytes and endothelial cells. Further enhancement by cyclosporine. Transplantation. 1988;46:575-580.
23. Locker GJ, Kapiotis S, Veitl M, et al. Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders. Br J Haematol. 1999;105:912-919.
24. Bitzan MM, Wang Y, Lin J, et al. Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J Clin Invest. 1998;101:372-382.
25. Eisenhauer PB, Jacewicz MS, Conn KJ, et al. Escherichia coli Shiga toxin 1 and TNF-alpha induce cytokine release by human cerebral microvascular endothelial cells. Microb Pathog. 2004;36:189-196.